Serum thymidine kinase 1 concentration as a prognostic factor of chemotherapy-treated non-Hodgkin's lymphoma patients

Journal of Cancer Research and Clinical Oncology

Volumn 136, Issue 8, 2010, Pages 1193-1199

  Pan, Zhu Lin ^a   Ji, Xing Ying ^a   Shi, Yan Min ^b   Zhou, Ji ^c   He, Ellen ^c   Skog, Sven ^c  

^a Department No 411   (China)

^b Diba Wu Hospital   (China)

^c Sino Swed Molecular Bio Medicine Research Institute   (China)

Author keywords

Chemotherapy; Enhanced chemiluminescent (ECL) dot blot assay; Non Hodgkin's lymphoma; Thymidine kinase 1

Indexed keywords

BETA ACTIN; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN Y ANTIBODY; PREDNISONE; THYMIDINE KINASE 1; UNCLASSIFIED DRUG; VINCRISTINE SULFATE; ACTIN; ANTINEOPLASTIC AGENT; CHOP PROTOCOL; THYMIDINE KINASE; TUMOR MARKER; VINCRISTINE;

ADULT; ARTICLE; BLOTTING; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; ENHANCED CHEMILUMINESCENT DOT BLOT ASSAY; ENZYME ANALYSIS; ENZYME BLOOD LEVEL; FEMALE; HUMAN; HUMAN CELL; LYMPHOMA CELL; MALE; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROGNOSIS; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; WESTERN BLOTTING; BLOOD; ENZYMOLOGY; MORTALITY; PATHOLOGY; RECEIVER OPERATING CHARACTERISTIC; SURVIVAL RATE; TIME;

ACTINS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; CYCLOPHOSPHAMIDE; DOXORUBICIN; HUMANS; LYMPHOMA, NON-HODGKIN; PREDNISONE; PROGNOSIS; ROC CURVE; SURVIVAL RATE; THYMIDINE KINASE; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; VINCRISTINE;

EID: 77954571250     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-010-0769-z     Document Type: Article

References (21)

1. Ferguson RE, Carroll HP, Harris E, Maher ER, Selby PJ, Banks RE (2005) Housekeeping proteins: a preliminary study illustrating some limitations as useful references in protein expression studies. Proteomics 5:566-577
2. Gronowitz JS, Hagberg H, Kallander CFR, Simonsson B (1983) The use of serum deoxythymidine kinase as a prognostic marker and in the monitoring of patients with non-Hodgkin's lymphoma. Br J Cancer 47:487-495
3. He Q, Wang N, Skog S, Eriksson S, Tribukait B (1996) Characterization of a peptide antibody against a C-terminal part of human and mouse cytosolic thymidine kinase, which is a marker for cell proliferation. Eur J Cell Biol 70:117-124
4. He E, Mao Y, Wu J et al. (2004) Cytosolic thymidine kinase is a speciWc histopathologic tumour marker for breast carcinomas. Int J Oncol 25:945-953
5. He Q, Zhang P, Zou L et al. (2005) Concentration of thymidine kinase 1 in serum (S-TK1) is a more sensitive proliferation marker in human solid tumours than its activity. Oncol Rep 14:1013-1019
6. HengZhi C, Zhou H, Tian NB, He E, Skog S (2008) Serological thymidine kinase 1 (STK1) indicates an elevated risk for development of malignant tumors. Anticancer Res 28:3897-3908
7. KauVman MG, Kelly TJ (1991) Cell cycle regulation of thymidine kinase: residues near the carboxyl terminus are essential for the speciWc degradation of the enzyme at mitosis. Mol Cell Biol 11:2538-2546
8. Ke PY, Chang CF (2004) Mitotic degradation of human thymidine kinase 1 is dependent on the anaphase-promoting complex/cyclosome- CDH1-mediated pathway. Mol Cell Biol 24:514-526
9. Kok M, Bonfrer JM, Korse CM, de Jong D, Kersten MJ (2003) Serum soluble CD27, but not thymidine kinase, is an independent prognostic factor for outcome in indolent non-Hodgkin's lymphoma. Tumour Biol 24:53-60
10. Poley S, Stieber P, Nussler V et al. (1997) Serum thymidine kinase in non-Hodgkin lymphomas with special regard to multiple myeloma. Anticancer Res 17:3025-3029
11. Rehn S, Glimelius B, Sundstrom CA (1991) Comparative study of proliferation-associated parameters in B-cell non-Hodgkin's lymphoma. Hematol Oncol 9:287-298
12. Sadamori N, Ichiba M, Mine M et al. (1995) Clinical significance of serum thymidine kinase in adult T-cell leukaemia and acute myeloid leukaemia. Br J Haematol 90:100-105
13. Suki S, Swan F, Tucker S et al. (1995) Risk classiWcation for large cell lymphoma using lactate dehydrogenase, beta-2 microglobulin, and thymidine kinase. Leuk Lymph 18:87-92
14. Topolcan O, Lubos Holubec L (2008) The role of thymidine kinase in cancer diseases. Expert Opin Med Diagn 2:129-140
15. Törnevik Y, Ullman BJ, Balzarini J et al. (1995) Cytotoxicity of 3′-azido- 3′-deoxythymidine correlates with 3′-azidothymidine- 5-monophosphate (AZTMP) levels, whereas anti-human ImmunodeWciency virus (HIV) activity correlates with 3′-azidothymidine 5-triphosphate (AZTTP) levels in cultured CEM T-lymphoblastoid cells. Biochem Pharmacol 49:829-837
16. Wu CJ, Yang RJ, Zhou J et al. (2003) Production and characterisation of a novel chicken IgY antibody raised against C-terminal peptide from human thymidine kinase 1. J Immunol Methods 277:157-169
17. Xu XH, Zhang YM, Shu XH et al. (2008) Serological thymidine kinase 1 reXects progression of pre-malignant and malignant tumours during therapy. Mol Med Rep 1:705-711
18. Zhang ZN, Shen D (1998) Diagnosis of blood disease and response criteria. The second version. Beijing Science Press, Beijing, pp 168-349
19. Zhang F, Li H, Pendleton AR et al. (2001) Thymidine kinase 1 immunoassay: a potential marker for breast cancer. Cancer Detect Prev 25:8-15
20. Zhang J, Jia Q, Zou S et al. (2006) Thymidine kinase 1: a proliferation marker for determining prognosis and monitoring the surgical outcome of primary bladder carcinoma patients. Oncol Rep 15:455-461
21. Zou L, Zhang PG, Zou S, Li Y, He Q (2002) The half-life of cytosolic thymidine kinase in serum by ECL dot bolt: a potential marker for monitoring the response to surgery of patients with gastric cancer. Int J Biol Marker 17:135-140